ʻIke Serological o ka maʻi lima, ka wāwae, a me ka waha

ʻO ka maʻi lima, ka wāwae, a me ka waha (HFMD).

ʻO ka maʻi lima, wāwae, a me ka waha ka mea maʻamau i waena o nā kamaliʻi. He maʻi lele loa, he hapa nui o nā maʻi asymptomatic, nā ala hoʻouna paʻakikī, a me ka hoʻolaha wikiwiki ʻana, hiki ke hoʻolaha nui i nā maʻi maʻi i loko o kahi manawa pōkole, e hoʻoikaika ana i ka hoʻomalu maʻi maʻi. I ka wā o nā maʻi ʻino, hiki ke loaʻa nā maʻi hui i nā kindergarten a me nā keʻena mālama keiki, a me ka hui pū ʻana o nā hihia. I ka makahiki 2008, ua hoʻokomo ʻia ʻo HFMD e ke Kuhina Ola i ka mālama ʻana i nā maʻi maʻi maʻi Cegory C.

 1

ʻO Coxsackievirus A16 (CA16) a me Enterovirus 71 (EV71) nā maʻi maʻamau e hoʻoulu ai i ka HFMD. Hōʻike ka ʻikepili Epidemiological i ka hele pinepine ʻana o CA16 me ka EV71, e alakaʻi ana i nā maʻi HFMD mau. I loko o kēia mau ʻino, ʻoi aku ka nui o nā maʻi CA16 ma mua o ka EV71, ʻoi aku ka nui o ka 60% o nā maʻi āpau. Hiki i ka HFMD i hoʻokumu ʻia e EV71 ke alakaʻi i ka pōʻino o ka ʻōnaehana nerve waena. ʻOi aku ka kiʻekiʻe o ka nui o nā hihia koʻikoʻi a me ka nui o ka make ma waena o nā maʻi i loaʻa i ka maʻi EV71 ma mua o ka poʻe i loaʻa i nā enterovirus ʻē aʻe, me ka nui o ka make maʻi maʻi a hiki i ka 10% -25%. Eia nō naʻe, ʻaʻole i hoʻokumu ʻia ka maʻi CA16 i nā maʻi e pili ana i ka ʻōnaehana pūpū waena e like me ka aseptic maningitis, brainstem encephalitis, a me ka poliomyelitis-like paralysis. No laila, he mea koʻikoʻi ka ʻike ʻokoʻa mua no ka mālama ʻana i nā ola o nā hihia koʻikoʻi.

ʻO ka hoʻokolohua lapaʻau

ʻO ka hoʻāʻo ʻana i kēia manawa no ka HFMD e pili ana i ka ʻike ʻana i ka waika nucleic o ka pathogen a me ka ʻike antibody serological. Hoʻohana ka hui ʻo Beier i ka enzyme-linked immunosorbent assay (ELISA) a me nā ʻano gula colloidal e hoʻomohala i ka Enterovirus 71 Antibody Test Kits a me Coxsackievirus A16 IgM Antibody Test Kits no ka ʻike ʻokoʻa o nā pathogens HFMD. Hāʻawi ka Serum antibody detection i ka naʻau kiʻekiʻe, kikoʻī maikaʻi, a maʻalahi, wikiwiki, a kūpono hoʻi no ka hoʻāʻo ʻana i nā lāʻau lapaʻau i nā keʻena mālama olakino ma nā pae āpau a no nā haʻawina nānā epidemiological nui.

Nā hōʻailona hōʻailona hōʻailona a me ka hōʻailona hōʻailona o ka maʻi EV71

ʻO ka ʻike kikoʻī o ka maʻi EV71 e hilinaʻi ʻia ma ka ʻike ʻana i nā antibodies EV71-RNA, EV71-IgM, a me EV71-IgG i loko o ka serum, a i ʻole ka ʻike ʻana o EV71-RNA i nā ʻano swab.

Ma hope o ka maʻi EV71, ʻike mua ʻia nā antibodies IgM, e piʻi ana i ka pule ʻelua. Hoʻomaka ka puka ʻana o nā antibodies IgG i ka lua o ka pule ma hope o ka maʻi maʻi a hoʻomau no ka manawa lōʻihi. He hōʻailona koʻikoʻi ka EV71-IgM o ka maʻi mua a i ʻole ka maʻi hou, e hoʻomaʻamaʻa i ka ʻike mua ʻana a me ka mālama ʻana i ka maʻi EV71. He hōʻailona koʻikoʻi ka EV71-IgG no ka hōʻailona ʻokoʻa o ka maʻi, pono no ka hoʻokolokolo maʻi epidemiological a me ka loiloi o ka pono o ka lāʻau lapaʻau. ʻO ka ʻike ʻana i ka hoʻololi ʻana i ka titer antibody ma waena o nā laʻana serum acute a convalescent hiki ke hoʻoholo i ke kūlana maʻi EV71; no ka laʻana, hiki ke noʻonoʻo ʻia kahi maʻi EV71 o ka maʻi EV71 i hoʻohālikelike ʻia i ka hoʻonui geometric ʻehā a ʻoi aku ka nui o ka titer antibody i ka serum convalescent.

Nā hōʻailona hōʻailona hōʻailona a me ka hōʻailona hōʻailona o ka maʻi CA16

ʻO ka ʻike kikoʻī o ka maʻi CA16 e hilinaʻi ʻia ma ka ʻike ʻana o CA16-RNA, CA16-IgM, a me CA16-IgG antibodies i loko o ka serum, a i ʻole ka ʻike ʻana o CA16-RNA i nā ʻano swab.

Ma hope o ka maʻi CA16, ʻike mua ʻia nā antibodies IgM, e piʻi ana i ka pule ʻelua. Hoʻomaka ka puka ʻana o nā antibodies IgG i ka lua o ka pule ma hope o ka maʻi maʻi a hoʻomau no ka manawa lōʻihi. ʻO CA16-IgM kahi hōʻailona koʻikoʻi o ka maʻi mua a i ʻole ka maʻi hou.

ʻO ke koʻikoʻi o ka hui ʻana o EV71 a me CA16 Antibody Testing

Hoʻokumu ʻia ka HFMD e kekahi mau enterovirus, me nā serotypes maʻamau ʻo EV71 a me CA16. Hōʻike ka noiʻi ʻo HFMD i hoʻokumu ʻia e ka maʻi maʻi CA16 maʻamau me nā hōʻailona maʻamau, ʻoi aku ka liʻiliʻi o nā pilikia, a me ka wānana maikaʻi. ʻO ka hoʻohālikelike ʻana, ʻo ka HFMD i hoʻokumu ʻia e EV71 e hōʻike pinepine ʻia me nā hōʻailona lapaʻau koʻikoʻi, ʻoi aku ka nui o nā hihia koʻikoʻi a me nā hihia make, a pili pinepine ʻia me nā pilikia o ka ʻōnaehana nerve waena. ʻO nā hōʻailona lapaʻau o ka HFMD he paʻakikī a nele pinepine i ka maʻamau, e hana paʻakikī loa i ka maʻi lapaʻau, ʻoi aku ka nui ma nā pae mua. ʻO ke koʻikoʻi o ka hoʻāʻo ʻana i ka antibody serum hui pū ʻia i ka hoʻololi ʻana i nā kaʻina hana hoʻokaʻawale maʻamau maʻamau, ʻike i ka pathogen serologically, a hāʻawi i kumu no ka maʻi maʻi, nā hoʻolālā lapaʻau, a me nā maʻi maʻi.

2

Nānā Hana Hana Huahana

EV71-IgM ELISAKitNānā Hana Hana

Slawa

No. oNā hihia

EV71-IgM Pono

EV71-IgM ʻAʻole

Snaʻauao

Sʻokoʻa

Nā hihia EV71 i hōʻoia ʻia

302

298

4

98.7%

—–

ʻAʻole-EV71 maʻi maʻi

25

1

24

—–

96%

Ka Lehulehu

700

—–

700

—–

100%

Hōʻike nā hualoaʻa:Hōʻike ka Beier EV71-IgM Test Kit i ka ʻike kiʻekiʻe a me ka kikoʻī maikaʻi no ka hoʻāʻo ʻana i ka serum mai nā poʻe maʻi EV71. Kumu ʻikepili: National Institute for Viral Disease Control and Prevention, Chinese CDC.

 

EV71-IgG ELISA Kit Ka Nānā Hana Hana (I)

Slawa

No. oNā hihia

EV71-IgG Pono

EV71-IgG ʻinoʻino

Snaʻauao

Sʻokoʻa

Nā hihia EV71 i hōʻoia ʻia

310

307

3

99.0%

—–

ʻAʻole-EV71 maʻi maʻi

38

0

38

—–

100%

Ka Lehulehu

700

328

372

—–

100%

 

EV71-IgG ELISA Kit Performance Analysis (II)

Slawa

No. oNā hihia

EV71-IgG Pono

EV71-IgG ʻinoʻino

Snaʻauao

Sʻokoʻa

Ka Lehulehu, Neutralization Test Positive

332

328

4

98.8%

—–

Ka Lehulehu, Ho'āʻo Neutralization Negative

368

—–

368

—–

100%

Hōʻike nā hualoaʻa:Hōʻike ka Beier EV71-IgG Test Kit i ka helu kiʻekiʻe o ka ʻike no ka serum mai nā poʻe me ka maʻi EV71 mau. Kumu ʻikepili: National Institute for Viral Disease Control and Prevention, Chinese CDC.

CA16-IgM ELISA Kit Ka Hana Hana Hana

Slawa

No. oNā hihia

CA16-IgM Pono

CA16-IgM ʻAʻole

Snaʻauao

Sʻokoʻa

Nā hihia CA16 i hōʻoia ʻia

350

336

14

96.0%

—–

Ka Lehulehu

659

0

659

—–

100%

Hōʻike nā hualoaʻa:Hōʻike ka Beier CA16-IgM Test Kit i kahi kiʻekiʻe o ka ʻike a me ka concordance maikaʻi. Kumu ʻikepili: National Institute for Viral Disease Control and Prevention, Chinese CDC.

 

EV71-IgM Ho'āʻo Kit (Colloidal Gold) Nānā Hana Hana

Slawa

No. oNā hihia

EV71-IgM Pono

EV71-IgM ʻAʻole

Snaʻauao

Sʻokoʻa

EV71-IgM Pono

90

88

2

97.8%

—–

Nā laʻana PCR maikaʻi / ʻaʻohe HFMD

217

7

210

—–

96.8%

Hōʻike nā hualoaʻa:Hōʻike ka Beier EV71-IgM Test Kit (Colloidal Gold) i ka ʻike kiʻekiʻe a me ka kikoʻī maikaʻi no ka hoʻāʻo ʻana i ka serum mai nā poʻe i loaʻa i ka maʻi EV71. Kumu ʻikepili: National Institute for Viral Disease Control and Prevention, Chinese CDC.

 

ʻO CA16-IgM hōʻike hōʻike (Colloidal Gold) Ka Hana Hana Hana

Slawa

No. oNā hihia

CA16-IgM Pono

CA16-IgM ʻAʻole

Snaʻauao

Sʻokoʻa

CA16-IgM Maikaʻi Laʻana

248

243

5

98.0%

—–

Nā laʻana PCR maikaʻi /

Nā hihia HFMD ʻole

325

11

314

—–

96.6%

Hōʻike nā hualoaʻa:Hōʻike ka Beier CA16-IgM Test Kit (Colloidal Gold) i ka ʻike kiʻekiʻe a me ka kikoʻī maikaʻi no ka ʻike ʻana i ka serum mai nā poʻe i loaʻa i ka maʻi CA16. Kumu ʻikepili: National Institute for Viral Disease Control and Prevention, Chinese CDC.


Ka manawa hoʻouna: ʻOkakopa-30-2025